Sales of Moderna’s COVID-19 vaccines reached $2.8 billion in the quarter – Kommersant

American pharmaceutical company Moderna reported about receipt of revenue in the fourth quarter of 2023 in the amount of $2.8 billion. Sales of the company’s vaccines in the United States during this period amounted to about $800 million, and abroad – about $2 billion. And despite the fact that this result is 45% worse, than in the same period in 2022, the company’s shares soared 10% at the opening of Nasdaq trading, as the results demonstrated were better than analysts’ forecasts. They expected the company’s revenue to be $2.5 billion.

Additionally, the company said its U.S. vaccine market share reached 48% during the fall COVID-19 season. A year earlier, its market share was only 37%. Finally, the company confirmed its own forecast for vaccine sales for 2024 – $4 billion.

In general, 2023 turned out to be much less successful for Moderna than 2022, which is due to the lifting of coronavirus restrictions around the world. Thus, the company’s sales decreased from $19.3 billion to $6.8 billion, and the net loss amounted to $4.7 billion against a profit of $8.4 billion in 2022.

Kirill Sarkhanyants